1. Home
  2. CAC vs TBPH Comparison

CAC vs TBPH Comparison

Compare CAC & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden National Corporation

CAC

Camden National Corporation

HOLD

Current Price

$50.57

Market Cap

781.2M

Sector

Finance

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.83

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAC
TBPH
Founded
1875
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
781.2M
824.9M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
CAC
TBPH
Price
$50.57
$16.83
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$45.50
$18.40
AVG Volume (30 Days)
91.3K
464.0K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
3.28%
N/A
EPS Growth
6.08
279.13
EPS
3.84
2.06
Revenue
$41,739,000.00
$15,386,000.00
Revenue This Year
$19.15
$1.04
Revenue Next Year
$6.05
N/A
P/E Ratio
$13.34
$8.36
Revenue Growth
16.96
N/A
52 Week Low
$35.00
$8.33
52 Week High
$52.17
$21.03

Technical Indicators

Market Signals
Indicator
CAC
TBPH
Relative Strength Index (RSI) 59.66 57.37
Support Level $41.94 $13.41
Resistance Level $51.37 $19.04
Average True Range (ATR) 1.09 0.48
MACD 0.14 0.17
Stochastic Oscillator 67.72 72.58

Price Performance

Historical Comparison
CAC
TBPH

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: